As­traZeneca poised to snag fast ap­proval for a front­line use of Imfinzi, adding to its grow­ing on­col­o­gy port­fo­lio

As­traZeneca ap­pears poised to hus­tle up a quick OK for its check­point in­hibitor Imfinzi for front­line bil­iary duct can­cer, a rare and ag­gres­sive form of can­cer that af­flicts few­er than 20,000 peo­ple a year in the US.

The phar­ma gi­ant put out word Wednes­day morn­ing that it bagged a pri­or­i­ty re­view from the FDA, cut­ting the re­view time to 6 months — or less, pro­vid­ed reg­u­la­tors want to push a quick ap­proval for a well-known can­cer ther­a­py. That sets up a launch lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER